Thursday, October 8, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 6, 2026

U.S. Defense Manufacturers Face A Rare Earth Supply Squeeze - OilPrice.com Market Commentary

View original at finance.yahoo.com
U.S. Defense Manufacturers Face A Rare Earth Supply Squeeze - OilPrice.com Market Commentary NEW YORK, March 6, 2026 /PRNewswire/ -- According to sources, the Pentagon will prohibit the use of rare earth magnet materials originating from China in U.S…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Pentagon will prohibit the use of rare earth magnet materials originating from China in U.S. military platforms beginning in 2027

    80% confidence
  • NORI-D project estimated to contain enough metals to meet requirements of 280 million electric vehicles

    80% confidence
  • Metallization is the least developed part of the value chain outside China and requires deep accumulated operating expertise

    80% confidence
  • SRC and REAlloys targeting roughly 400 tonnes of rare earth metal output annually by end of 2027, rising toward 600 tonnes as Phase 1 scales

    80% confidence
  • Replicating rare earth metallization capability typically takes three to seven years or more with meaningful technical and qualification risk

    80% confidence
  • Rare earth sourcing restrictions require traceability down to mining level across multi-tier supplier networks

    80% confidence
  • REalloys has already solved the hardest part proving rare earth metallization can be done domestically to customer specifications

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com